2026-04-14T04:39:45Zhttps://recercat.cat/oai/request

oai:recercat.cat:10230/235722025-12-26T11:29:49Zcom_2072_6col_2072_452952

00925njm 22002777a 4500 dc Balbás Martínez, Cristina author Rodríguez Pinilla, María author Casanova, Ariel author Domínguez, Orlando author Pisano, David G. author Gómez López, Gonzalo author Lloreta, Josep, 1958- author Lorente Garin, José Antonio author Malats i Riera, Núria author Real, Francisco X. author 2015-05-13T10:42:02Z 2015-05-13T10:42:02Z 2013 Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathological, genetic, and epigenetic levels. Exome sequencing has identified ARID1A as a novel tumor suppressor gene coding for a chromatin remodeling protein that is mutated in UBC. Here, we assess ARID1A alterations in two series of patients with UBC. In the first tumor series, we analyze exons 2–20 in 52 primary UBC and find that all mutant tumors belong to the aggressive UBC phenotype (high grade non-muscle invasive and muscle invasive tumors) (P = 0.05). In a second series (n = 84), we assess ARID1A expression using immunohistochemistry, a surrogate for mutation analysis, and find that loss of expression increases with higher stage/grade, it is inversely associated with FGFR3 overexpression (P = 0.03) but it is not correlated with p53 overexpression (P = 0.30). We also analyzed the expression of cytokeratins in the same set of tumor and find, using unsupervised clustering, that tumors with ARID1A loss of expression are generally KRT5/6-low. In this patient series, loss of ARID1A expression is also associated with worse prognosis, likely reflecting the higher prevalence of losses found in tumors of higher stage and grade. The independent findings in these two sets of patients strongly support the notion that ARID1A inactivation is a key player in bladder carcinogenesis occurring predominantly in FGFR3 wild type tumors. This work was supported in part by grant Consolider ONCOBIO from Ministerio de Economía y Competitividad, Spain; grants 00/0745, PI051436, PI061614, G03/174 and Red Temática de Investigación Cooperativa en Cáncer (grant RD06/0020-RTICC) from Instituto de Salud Carlos III; Asociación Española Contra el Cáncer; and EU FP7 grant agreement numbers 201663 (UROMOL) and 201333 (DECANBIO). CBM is recipient of a La Caixa International PhD Fellowship Fetge -- Càncer Proteïnes ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors